Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Go back to Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria| Regeneron (NASDAQ: REGN) | Delayed: 614.09 +1.59 (0.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $607.92 | 52 Week Low | $325.35 | |||
| Day High | $617.50 | P/E | 161.18 | |||
| Day Low | $607.92 | EPS | $3.81 | |||
| Volume | 58,761 | |||||
